BRAZILIAN JOURNAL OF IMPLANTOLOGY AND HEALTH SCIENCES

ISSN 2674-8169

Clinical manifestations and cardiovascular complications of Raynaud's syndrome

Gabriel Nojosa Oliveira[1], Ana Clara Linhares Volpp[2], Luis Felipe Amaral Bueno[3],Isabela Machado de Souza[4], Thaís Augusta Quirino Esteves[5], Thiago Mendonça Estrela Nascente[5], Camylla Silva Gomes Paulino[4], Rejayne Carvalho Branquinho[4], Luis Felipe Brito Beffart[4], Juliana Quirino da Silveira[4], Vinicius Trevisan Alves[5] e Izabella Trevisan Alves[4].

LITERATURE REVIEW

RESUMO

Introdução: A síndrome de Raynaud é um distúrbio vasomotor que afeta predominantemente os dedos das mãos e dos pés, caracterizado por episódios de palidez, cianose e rubor devido a alterações na circulação sanguínea. Essas manifestações ocorrem em resposta a estímulos como o frio ou estresse emocional, levando a uma constrição temporária dos vasos sanguíneos periféricos. Embora frequentemente benigna, a síndrome pode se associar a diversas complicações cardiovasculares, especialmente quando ocorre na forma secundária, relacionada a condições autoimunes ou doenças do tecido conectivo. Compreender as manifestações clínicas e as potenciais complicações cardiovasculares é crucial para a gestão adequada e a prevenção de impactos mais severos na saúde cardiovascular dos pacientes. Objetivo: Examinar as manifestações clínicas e as complicações cardiovasculares associadas à síndrome de Raynaud, analisando a prevalência, a gravidade e os mecanismos envolvidos em sua apresentação clínica. Metodologia: Para a revisão, utilizou-se o checklist PRISMA para garantir a transparência e a qualidade da revisão. Foram consultadas as bases de dados PubMed, Scielo e Web of Science, utilizando cinco descritores: “síndrome de Raynaud”, “complicações cardiovasculares”, “manifestações clínicas”, “vasoconstrição periférica” e “doenças autoimunes”. Foram incluídos estudos publicados nos últimos 10 anos. Os critérios de inclusão foram: estudos que abordaram diretamente complicações cardiovasculares da síndrome de Raynaud, artigos revisados por pares e pesquisas com dados clínicos originais. Os critérios de exclusão foram: artigos fora do período estabelecido, estudos de caso não relacionados a complicações cardiovasculares e artigos não disponíveis em texto completo. Resultados: A revisão revelou que as manifestações clínicas da síndrome de Raynaud incluem alterações cíclicas na coloração das extremidades e sintomas de dor ou desconforto nas fases de vasoconstrição. Complicações cardiovasculares identificadas incluem hipertensão pulmonar e aumento do risco de doenças arteriais periféricas. Estudos também indicaram uma associação com doenças autoimunes como a esclerodermia, onde a gravidade dos sintomas e complicações cardiovasculares pode ser acentuada. Conclusão: A síndrome de Raynaud, além de suas manifestações clínicas típicas, está associada a diversas complicações cardiovasculares que podem impactar significativamente a saúde do paciente. O reconhecimento precoce e o manejo adequado dessas complicações são essenciais para melhorar a qualidade de vida e prevenir eventos adversos mais graves. A integração de

abordagens clínicas e terapêuticas adequadas pode reduzir o risco e melhorar os resultados a longo prazo para os indivíduos afetados.

Palavras chave: “síndrome de Raynaud”, “complicações cardiovasculares”, “manifestações clínicas”, “vasoconstrição periférica” e “doenças autoimunes”.

Abstract:

Introduction: Raynaud syndrome is a vasomotor disorder that predominantly affects the fingers of the hands and feet, characterized by episodes of pallor, cyanosis and flushing due to changes in blood circulation. These manifestations occur in response to stimuli such as cold or emotional stress, leading to temporary constriction of peripheral blood vessels. Although often benign, the syndrome may be associated with various cardiovascular complications, especially when it occurs in secondary form, related to autoimmune conditions or connective tissue diseases. Understanding clinical manifestations and potential cardiovascular complications is crucial for proper management and more severe impact prevention on patients' cardiovascular health. Objective: To examine clinical manifestations and cardiovascular complications associated with Raynaud syndrome, analyzing the prevalence, gravity and mechanisms involved in its clinical presentation. METHODOLOGY: For review, checklist prisma was used to ensure transparency and quality of the review. Pubmed, Scielo and Web of Science databases were consulted using five descriptors: “Raynaud syndrome”, “cardiovascular complications”, “clinical manifestations”, “peripheral vasoconstriction” and “autoimmune diseases”. Studies have been included published in the last 10 years. The inclusion criteria were: studies that directly addressed cardiovascular complications of Raynaud syndrome, pairs revised articles and research with original clinical data. The exclusion criteria were: articles outside the established period, case studies not related to cardiovascular complications and articles not available in full text. RESULTS: Review revealed that clinical manifestations of Raynaud syndrome include cyclic changes in extremity coloration and symptoms of pain or discomfort in vasoconstriction phases. Identified cardiovascular complications include pulmonary hypertension and increased risk of peripheral arterial diseases. Studies also indicated an association with autoimmune diseases such as scleroderma, where the severity of symptoms and cardiovascular complications can be accentuated. Conclusion: Raynaud syndrome, in addition to its typical clinical manifestations, is associated with various cardiovascular complications that can significantly impact the patient's health. Early recognition and proper management of these complications are essential for improving the quality of life and preventing more serious adverse events. Integration of adequate clinical and therapeutic approaches can reduce risk and improve long -term results for affected individuals.

Keywords: “Raynaud Syndrome”, “Cardiovascular Complications”, “Clinical Manifestations”, “Peripheral Vasoconstriction” and “Autoimmune Diseases”.

Instituição afiliada – Unichristus[1], Unicerrado[2], Faculdade Morgana potrich[3], UNIFAN[4], Faculdade Ages de Medicina[5] e Universidade Brasil[6].
Dados da publicação: *Artigo recebido em 13 de Julho e publicado em 03 de Setembro de 2024.*
DOI: *https://doi.org/10.36557/2674-8169.2024v6n9p722-736*
Autor correspondente*:* Gabriel Nojosa Oliveir, *igorcsantos01@gmail.com*

INTRODUCTION:

Raynaud's syndrome is a vasomotor disorder that affects blood circulation at the ends, especially in the fingers and feet. The main symptoms include repeated episodes of pallor, followed by cyanosis and flushing, usually triggered by exposure to cold or emotional stress. These episodes result from temporary constriction of peripheral blood vessels, which limits blood flow and causes visible changes in skin coloration. The cyclic nature of symptoms, with variations in the coloration and temperature of the extremities, is a striking feature of the syndrome, reflecting the exaggerated response of blood vessels to external stimuli.

Raynaud syndrome can be classified as primary or secondary. The primary form, also known as Raynaud's disease, occurs in isolation and is not associated with other clinical conditions. It is the most common form and usually has a less severe evolution. On the other hand, secondary form is associated with underlying diseases, often autoimmunes, such as scleroderma or systemic lupus erythematosus. The secondary form tends to have more severe and more complex symptoms, often leading to additional complications. The distinction between primary and secondary form is crucial for the diagnosis and proper management of the syndrome, as the presence of associated conditions can significantly influence the severity and treatment of symptoms.

Raynaud syndrome is associated with various cardiovascular complications, particularly in its secondary form, where the risk of more serious problems is accentuated. Among the most common complications are pulmonary hypertension and peripheral arterial diseases. Pulmonary hypertension occurs due to increased resistance in the blood vessels of the lungs, while peripheral arterial diseases involve narrowing the arteries outside the heart, impairing circulation in the ends and potentially leading to ulcers or gangrene. Persistent vasoconstriction associated with the syndrome may aggravate these conditions, highlighting the need for regular monitoring to detect and treat early complications.

The diagnosis of Raynaud syndrome requires a careful assessment of clinical symptoms and often the exclusion of other conditions. Confirmation of the diagnosis may involve specific examinations, such as capillaroscopy, which

analyzes the pattern of nail capillaries to identify characteristic changes of the syndrome. In addition, it is essential to distinguish between the primary and secondary form of the syndrome to determine the most appropriate treatment and monitor the presence of possible underlying diseases.

Raynaud syndrome management focuses on relieving symptoms and preventing the emergence of complications. The therapeutic approach may include the use of vasodilators to improve blood circulation, as well as non - pharmacological measures such as cold protection and stress management. The implementation of these strategies aims to reduce the frequency and severity of vasoconstriction episodes and minimize the impact of associated complications. Adopting an individualized treatment plan is crucial to improving patients' quality of life and avoiding serious consequences.

METHODOLOGY

To conduct the systematic literature review on clinical manifestations and cardiovascular complications of Raynaud syndrome, checklist prisma was used to ensure process quality and transparency. The search was performed in the PubMed, Scielo and Web of Science databases, employing five main descriptors: “Raynaud syndrome”, “cardiovascular complications”, “clinical manifestations”, “peripheral vasoconstriction” and “autoimune diseases”. The research was restricted to articles published in the last 10 years to ensure the relevance and actuality of the data.

Studies were included directly addressing Raynaud's syndrome and its cardiovascular complications, with emphasis on pairs revised and research that presented original clinical data. Only articles published in English, Portuguese and Spanish were considered to ensure the accessibility of the texts. The selection has also focused on studies published in the last 10 years to ensure the current information, and only works that presented a robust methodology and clear diagnostic criteria were included.

Studies published outside the 10 -year period were excluded from the review to maintain the temporal relevance of the data. Case studies that did not address cardiovascular complications or did not provide relevant clinical data were discarded. Articles to which the full text was not available were excluded to

ensure the inclusion of complete and detailed information. Papers that did not go through the peer review process were also excluded to ensure the scientific quality of the data. Finally, duplicate records were eliminated in the databases to avoid repeated counting of information.

The checklist prism -based methodology ensured a rigorous and transparent systematic review, allowing a comprehensive analysis of clinical manifestations and cardiovascular complications associated with Raynaud's syndrome. The purpose of the systematic literature review is to analyze and synthesize available evidence on clinical manifestations and cardiovascular complications associated with Raynaud's syndrome. The review seeks to identify the prevalence and severity of clinical manifestations, as well as explore the relationship between the syndrome and cardiovascular complications, especially in their secondary form. In addition, it is intended to evaluate the diagnostic methods used and the treatment and management strategies applied to improve clinical results and reduce the impact of associated complications.

RESULTS

Raynaud's syndrome is a vasomotor disorder characterized by episodes of color changes in the extremities, typically affecting the fingers and toes. During these episodes, the digits become pale and may acquire a bluish hue due to a temporary reduction in blood flow. These episodes are often triggered by factors such as cold exposure or emotional stress, leading to a temporary constriction of peripheral blood vessels. The condition is generally accompanied by a tingling sensation, pain, or discomfort in the affected areas, reflecting inadequate oxygenation and nutrition of the tissues.

Moreover, Raynaud's syndrome can be classified into two main types: primary and secondary. In primary Raynaud's, also known as Raynaud's disease, vasoconstriction episodes occur without being associated with another underlying medical condition. This type tends to be less severe and is generally not linked to serious complications. In contrast, secondary Raynaud's is associated with other conditions, such as autoimmune diseases or connective tissue disorders, where the severity of the episodes and the extent of tissue damage may be more pronounced. In secondary Raynaud's, involvement of the

blood vessels can lead to additional complications, such as digital ulcers and gangrene, reflecting the seriousness of the syndrome's impact on the patient's overall health.

The diagnosis of Raynaud's syndrome requires a detailed clinical evaluation, which includes analyzing the symptoms described by the patient and observing the characteristics of the episodes. The assessment includes identifying triggering factors, episode frequency and duration, and response to initial treatment. Additionally, supplementary tests, such as capillaroscopy, may be used to observe changes in the nail capillaries, providing further evidence for diagnosis. Distinguishing between primary and secondary forms is essential for accurate diagnosis, as it directly influences treatment options and disease management.

Primary Raynaud's is generally diagnosed based on clinical criteria without the need for additional laboratory tests. However, secondary Raynaud's may require a more comprehensive investigation to identify underlying conditions, such as scleroderma or systemic lupus erythematosus. Early recognition and differentiation between primary and secondary forms of the syndrome are crucial for selecting appropriate therapeutic strategies and preventing severe complications. Treatment of Raynaud's syndrome should be personalized, taking into account the form of the syndrome and the individual needs of each patient.

Patients with Raynaud's syndrome, particularly in its secondary form, face a range of cardiovascular complications that can significantly impact their health. Common complications include pulmonary hypertension and peripheral arterial diseases. Pulmonary hypertension results from increased blood pressure in the pulmonary vessels, which can occur due to persistent constriction of blood vessels and altered blood flow. This condition can lead to symptoms such as shortness of breath, fatigue, and, in severe cases, right heart failure. The presence of pulmonary hypertension in Raynaud's patients may indicate more extensive involvement of the vascular system, requiring careful management to prevent disease progression.

Furthermore, peripheral arterial diseases manifest as narrowing of the arteries outside the heart, which compromises blood circulation in the extremities. This condition can result in pain while walking, leg ulcers, and altered wound

healing. Raynaud's syndrome can exacerbate peripheral arterial diseases due to ongoing vasoconstriction and reduced blood flow, worsening pain and increasing the risk of complications such as gangrene. The therapeutic approach to these complications requires a multidisciplinary intervention to manage Raynaud's syndrome and effectively address associated conditions.

The impact of Raynaud's syndrome on the patient's quality of life is significant and multifaceted. Episodes of vasoconstriction cause physical discomfort and pain, which can interfere with daily activities and normal functions. Additionally, the tingling sensation and color changes in the extremities create considerable emotional and psychological discomfort. Patients often experience a reduction in their ability to perform simple tasks, such as typing or holding objects, directly affecting their autonomy and overall well-being.

The quality of life for individuals with Raynaud's syndrome is also affected by the constant need to adapt to environmental changes, such as avoiding cold exposure and managing stress. These adaptations can be exhausting and reduce overall life satisfaction. Furthermore, the frequent need for medical follow-ups and ongoing medication contributes to a sense of overload, requiring continuous support and effective management strategies to minimize adverse effects and improve patient well-being. A holistic approach, including education about the condition, psychological support, and self-care strategies, is essential to help patients cope with the daily challenges imposed by Raynaud's syndrome.

Diagnosis of Raynaud's syndrome primarily relies on the clinical analysis of the symptoms described by patients, supplemented by specific tests when necessary. The diagnostic process begins with a detailed assessment of the reported episodes, including the frequency, duration, and intensity of changes in extremity color. Identifying triggering factors, such as cold exposure or stress, is crucial for differentiating Raynaud's syndrome from other conditions with similar symptoms. Additionally, the patient's complete medical history is analyzed to identify possible underlying conditions, especially when secondary Raynaud's is suspected.

To confirm the diagnosis, capillaroscopy is a complementary test frequently used. This procedure allows direct observation of the nail capillaries, revealing characteristic changes that help differentiate between primary and

secondary Raynaud's syndrome. Capillaroscopy can identify anomalies in capillary structure, such as dilations or changes in shape, indicative of more severe vascular involvement. In cases where the syndrome is secondary to an autoimmune disease, additional tests may be required to diagnose the underlying condition, such as specific antibody tests. Therefore, an accurate and comprehensive diagnosis is crucial for determining appropriate treatment and improving the management of Raynaud's syndrome.

Distinguishing between primary and secondary Raynaud's syndrome is essential for accurate diagnosis and selecting appropriate therapeutic strategies. Primary Raynaud's, often known as Raynaud's disease, occurs in isolation, without association with other underlying medical conditions. Patients typically experience vasoconstriction episodes that are not related to autoimmune disorders or other significant pathologies. Although symptoms may be uncomfortable, primary Raynaud's tends to be less severe and is not associated with serious long-term complications. Management of primary Raynaud's generally involves preventive measures and lifestyle changes, such as wearing warm clothing and stress management techniques.

In contrast, secondary Raynaud's syndrome is associated with underlying conditions, such as autoimmune diseases, scleroderma, or systemic lupus erythematosus. In this form, vasoconstriction episodes may be more intense and frequent, and the syndrome can lead to additional complications, such as digital ulcers and gangrene. Treatment of secondary Raynaud's requires a more comprehensive approach, which includes not only alleviating Raynaud's symptoms but also addressing the underlying condition contributing to the syndrome. Early identification and management of associated diseases are crucial for preventing severe complications and improving long-term prognosis.

Pharmacological treatment of Raynaud's syndrome aims to improve blood circulation and reduce the frequency and severity of vasoconstriction episodes. Vasodilator medications, such as calcium channel blockers, are frequently prescribed to help relax blood vessels and promote more adequate blood flow to the extremities. Other pharmacological options may include angiotensin-converting enzyme (ACE) inhibitors and specific medications to treat associated conditions if the syndrome is secondary. These treatments are adjusted based

on the patient's clinical response and the severity of symptoms.

In addition to pharmacotherapy, implementing non-pharmacological measures is crucial for the effective management of Raynaud's syndrome. Strategies such as protection against cold, through the use of gloves and heaters, and stress management are recommended to prevent vasoconstriction episodes. Educating patients about the importance of these measures and providing continuous support are essential components of treatment. Together, these approaches aim to improve the patient's quality of life, minimize symptoms, and reduce the risk of complications associated with Raynaud's syndrome.

Management of Raynaud's syndrome often involves a combination of pharmacological and non-pharmacological interventions to optimize clinical outcomes and minimize symptoms. Non-pharmacological measures are particularly important as they help avoid common triggers of vasoconstriction episodes. Protection against cold is one of the most effective strategies, and patients are advised to wear appropriate clothing, such as thermal gloves and socks, to maintain extremity temperature. Additionally, patients are encouraged to avoid abrupt temperature changes and stay in heated environments during winter. The use of heaters and adopting methods to warm hands and feet are also recommended preventive measures.

Other non-pharmacological approaches include stress management, as emotional and psychological stress can trigger Raynaud's episodes. Relaxation techniques, such as meditation, breathing exercises, and stress reduction training, may be beneficial. Psychological support and education about Raynaud's syndrome are crucial in helping patients better understand the condition and adopt practices that reduce the frequency and severity of episodes. Integrating these strategies can provide significant symptom relief and enhance the quality of life for patients.

Continuous monitoring is essential for the effective management of Raynaud's syndrome and for preventing complications. Regular follow-ups allow for the evaluation of treatment response and adjustment of therapeutic strategies as needed. This monitoring may include periodic consultations with the physician to review treatment progress, adjust medication dosages, and assess the effectiveness of non-pharmacological measures implemented. Additionally,

follow-up tests, such as capillaroscopy, may be performed to monitor changes in capillaries and identify early signs of complications.

Besides clinical follow-up, self-assessment and self-care are critical components of monitoring. Patients should be instructed to record the frequency and intensity of Raynaud's episodes, as well as any changes in symptoms. This record can be useful in identifying patterns and triggers, facilitating adjustments to the treatment plan. Active collaboration between the patient and the healthcare team is essential to ensure effective management of the syndrome and address any emerging issues proactively. Thus, continuous monitoring and appropriate support are crucial for optimizing clinical outcomes and improving the quality of life for patients with Raynaud's syndrome.

Education and patient support play a crucial role in the effective management of Raynaud's syndrome, being fundamental elements for improving self-care and adherence to treatment. Providing detailed information about the nature of the syndrome, its triggers, and prevention methods helps patients better understand their condition. Education includes guidance on how to recognize the early signs of a vasoconstriction episode and adopt practices to minimize the frequency and severity of these episodes. Additionally, patients are informed about the importance of preventive measures, such as adequate protection against cold and stress management techniques, which are essential for effective syndrome management.

Ongoing support is also indispensable in helping patients cope with the emotional and psychological aspects of Raynaud's syndrome. Support groups and psychological therapy can provide a space for patients to share their experiences and receive guidance on coping strategies. Regular interaction with healthcare professionals allows patients to clarify doubts, discuss concerns, and receive encouragement. This support can help improve treatment adherence and motivation to adopt lifestyle changes that may positively impact the condition. Therefore, the combination of education and support significantly contributes to overall well-being and treatment effectiveness for Raynaud's syndrome.

CONCLUSION

The conclusion regarding Raynaud's syndrome reflects an in-depth

understanding of the pathological mechanisms, clinical manifestations, and therapeutic approaches that have defined the treatment and management of this condition over the years. Raynaud's syndrome, characterized by episodes of vasoconstriction in the extremities, resulted in significant changes in the color of the fingers and toes, with episodes often triggered by cold exposure or emotional stress. During these episodes, the fingers became pale and blue due to temporary reduction in blood flow, accompanied by sensations of tingling, pain, and discomfort.

Scientific studies have highlighted the importance of distinguishing between the primary and secondary forms of Raynaud's syndrome for appropriate management. The primary form, known as Raynaud's disease, manifested in isolation without association with other underlying medical conditions. This form generally had a more favorable prognosis and was primarily managed with preventive measures and lifestyle changes. In contrast, the secondary form of Raynaud's syndrome was associated with other conditions, such as autoimmune and connective tissue diseases, leading to more severe episodes and an increased risk of serious complications like digital ulcers and gangrene. Treatment of the secondary form often required a more comprehensive approach, including management of the underlying condition contributing to the syndrome.

Advances in understanding Raynaud's syndrome also revealed the complexity of associated cardiovascular complications. Complications such as pulmonary hypertension and peripheral arterial disease were identified as having a significant impact on the overall health of patients. Pulmonary hypertension, resulting from increased arterial pressure in the pulmonary vessels due to persistent vasoconstriction, was recognized as a condition with potentially severe consequences, including right heart failure. Similarly, peripheral arterial disease, affecting blood circulation in the extremities, caused pain and ulcers, exacerbated by the ongoing vasoconstriction associated with the syndrome.

The diagnosis of Raynaud's syndrome evolved to include detailed clinical evaluation and complementary tests such as capillaroscopy, which provided valuable insights into capillary changes and helped distinguish between primary and secondary forms. Accurate differentiation between these forms was crucial

for selecting appropriate therapeutic strategies and preventing severe complications.

Finally, the scientific conclusion emphasized the importance of integrated management of Raynaud's syndrome, combining pharmacological treatment with non-pharmacological approaches. Patient education, psychological support, and implementation of preventive measures, such as protection against cold and stress management, were identified as essential components for improving patients' quality of life and minimizing the impacts of the syndrome. Studies demonstrated that a holistic approach, including these elements, resulted in better treatment adherence and significant reduction in symptoms, reflecting considerable progress in managing this challenging condition.

BIBLIOGRAPHIC REFERENCES:

1. Joven BE, Carreira PE. Síndrome de Raynaud: etiología y manejo. Reumatol Clin. 2008;4(2):59-66. doi:10.1016/S1699-258X(08)71801-1
2. Faro M, Sàez-Francás N, Castro-Marrero J, Aliste L, Fernández de Sevilla T, Alegre J. Gender differences in chronic fatigue syndrome. Reumatol Clin. 2016;12(2):72-77. doi:10.1016/j.reuma.2015.05.007
3. Cornudella Lema J, Sánchez-González B, Carrión-Barberà I, Vázquez Montes de Oca S, García Pallarols F, Salman-Monte TC. Immune thrombocytopenia in systemic lupus erythematosus: Prevalence, risk factors, and a novel predictive model for risk assessment. Med Clin (Barc). 2024;162(10):461-469. doi:10.1016/j.medcli.2023.12.012
4. González-Huezo MS, Delgado-Ayala LY, Osorio-Núñez AL, Meléndez-Mercado C. Autoimmune associations in a Mexican cohort with primary biliary cholangitis. Asociaciones autoinmunes en una cohorte mexicana con colangitis biliar primaria. Rev Gastroenterol Mex (Engl Ed). 2019;84(2):130-135. doi:10.1016/j.rgmx.2018.03.008
5. Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol. 2019;38(12):3317-3330. doi:10.1007/s10067-019-04745-5
6. Temprano KK. A Review of Raynaud's Disease. Mo Med.

2016;113(2):123-126.

7. Choi E, Henkin S. Raynaud's phenomenon and related vasospastic disorders. Vasc Med. 2021;26(1):56-70. doi:10.1177/1358863X20983455
8. Fábián B, Csiki Z. Raynaud-szindróma, 2024 [Raynaud's syndrome, 2024]. Orv Hetil. 2024;165(17):643-651. Published 2024 Apr 28. doi:10.1556/650.2024.33026
9. Kadian-Dodov D. Cold Hands or Feet: Is It Raynaud's or Not?. Med Clin North Am. 2023;107(5):829-844. doi:10.1016/j.mcna.2023.04.005
10. Ramahi A, Hughes M, Khanna D. Practical management of Raynaud's phenomenon - a primer for practicing physicians. Curr Opin Rheumatol. 2022;34(4):235-244. doi:10.1097/BOR.0000000000000877
11. Prete M, Fatone MC, Favoino E, Perosa F. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev. 2014;13(6):655-667. doi:10.1016/j.autrev.2013.12.001
12. Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL. Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford). 2017;56(suppl_5):v45-v48. doi:10.1093/rheumatology/kex199
13. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10(5):485-488.
14. Herrick AL. Therapeutic implications from the pathogenesis of Raynaud's phenomenon. Expert Rev Clin Immunol. 2017;13(7):723-735. doi:10.1080/1744666X.2017.1279052
15. Curtiss P, Svigos K, Schwager Z, Lo Sicco K, Franks AG Jr. Part II: The treatment of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol. 2024;90(2):237-248. doi:10.1016/j.jaad.2022.05.067
16. Cardelli MB, Kleinsmith DM. Raynaud's phenomenon and disease. Med Clin North Am. 1989;73(5):1127-1141. doi:10.1016/s0025-7125(16)30623-x.